Live Breaking News & Updates on Immune And Biological Products

Stay updated with breaking news from Immune and biological products. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Russia and its vaccine 'unpopular' in the West due to unfair competition - Kremlin - Russian Politics & Diplomacy


Russia is not popular in the West in general, Presidential spokesman Dmitry Peskov said
© Anton Novoderzhkin/TASS
MOSCOW, December 19. /TASS/. The West s attitude towards Russia and the Russian Sputnik V coronavirus vaccine is related to competition issues, Presidential spokesman Dmitry Peskov said in an interview with Rossiya 1 TV channel.
Russia is not popular in the West in general. Not because it is bad, but because it is becoming too good, Peskov said. It is very simple: this is competition, not always fair, he added.
On August 11, Russia was the first in the world to register a vaccine against coronavirus named Sputnik V, developed by the Gamaleya National Center of Epidemiology and Microbiology. Later, another Russian vaccine was registered, developed by the Research Center of Virology and Biotechnology Vector. The third vaccine, created by the Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian ....

Orenburgskaya Oblast , Stavropol Skiy Kray , Dmitry Peskov , Chumakov Federal Scientific Center , Research Center , Gamaleya National Center , Immune And Biological Products , Russian Academy , ஆராய்ச்சி மையம் , நோய் எதிர்ப்பு சக்தி மற்றும் உயிரியல் ப்ராடக்ட்ஸ் , ரஷ்ய கலைக்கழகம் ,

Up to 80% of Russians will be vaccinated against coronavirus by fall 2021, developer says


Up to 80% of Russians will be vaccinated against coronavirus by fall 2021, developer says
This disease will be vaccine-controlled, Director of the Gamaleya National Center of Epidemiology and Microbiology Alexander Gintsburg said
MOSCOW, December 19. /TASS/. Up to 80% of Russians are expected to be vaccinated against coronavirus by the fall of 2021, Director of the Gamaleya National Center of Epidemiology and Microbiology Alexander Gintsburg said in an interview with Rossiya 1 TV channel.
If a month, and this is quite realistic for our domestic consumption, we will produce 5-6 mln doses of vaccine, then by the end of fall 2021 we should vaccinate 70-80% of our population, that is, this disease will be vaccine-controlled, he said. ....

Stavropol Skiy Kray , Orenburgskaya Oblast , Alexander Gintsburg , Chumakov Federal Scientific Center , Research Center , Gamaleya National Center , Microbiology Alexander Gintsburg , Immune And Biological Products , Russian Academy , ஆராய்ச்சி மையம் , நோய் எதிர்ப்பு சக்தி மற்றும் உயிரியல் ப்ராடக்ட்ஸ் , ரஷ்ய கலைக்கழகம் ,

Russia developing 26 vaccine options for COVID-19


Russia developing 26 vaccine options for COVID-19
Photo courtesy of TASS
MINSK, 16 December (BelTA) – Russian scientists are developing 26 vaccine options for COVID-19 at 17 research centers, Head of the Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being [Rospotrebnadzor] Anna Popova said, TASS reports.
“At present Russia is developing 26 vaccine options for COVID-19 at 17 research centers,” Anna Popova said at a meeting of the chiefs of consumer safety and sanitary watchdogs of the BRICS countries.
Speaking about EpiVacCorona, a COVID-19 vaccine developed by the Novosibirsk-based State Research Center of Virology and Biotechnology VECTOR, the Rospotrebnadzor chief informed that EpiVacCorona post-registration trials on 150 volunteers older than 60 years wrap up on 16 December. ....

Stavropol Skiy Kray , Belarus General , Russian Federation , December Bel , Anna Popova , Chumakov Federal Scientific Center , Russian Academy , Gamaleya National Research Institute Of Epidemiology , Research Center , Federal Service , Consumer Rights Protection , Human Wellbeing , Novosibirsk Based State Research Center , Gamaleya National Research Institute , State Research Center , Immune And Biological Products , பெலாரஸ் ஜநரல் , ரஷ்ய கூட்டமைப்பு , டிசம்பர் பெல் , அண்ணா பாபூவ , ரஷ்ய கலைக்கழகம் , ஆராய்ச்சி மையம் , கூட்டாட்சியின் சேவை , நுகர்வோர் உரிமைகள் ப்ரொடெக்ஶந் , மனிதன் நல்வாழ்வு , நிலை ஆராய்ச்சி மையம் ,

Work on 26 coronavirus vaccine options underway in Russia, says watchdog chief


Russia has so far registered two domestic coronavirus vaccines
MOSCOW, December 16. /TASS/. Work on 26 coronavirus vaccine options is underway in Russia, Head of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing Anna Popova said at a meeting of the sanitary watchdog chiefs from BRICS countries.
Work on 26 vaccine options is underway at 17 research centers, she pointed out.
Read also
Russia has so far registered two domestic coronavirus vaccines, one of which was developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology and the other one by the State Research Center of Virology and Biotechnology Vector. A third vaccine, developed by the Russian Academy of Sciences’ Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products, may be registered in the near future. ....

Stavropol Skiy Kray , Development Of Products , Gamaleya Scientific Research Institute Of Epidemiology , Research Center , Gamaleya Scientific Research Institute , State Research Center , Russian Academy , Science Chumakov Federal Scientific Center , Immune And Biological Products , வளர்ச்சி ஆஃப் ப்ராடக்ட்ஸ் , ஆராய்ச்சி மையம் , நிலை ஆராய்ச்சி மையம் , ரஷ்ய கலைக்கழகம் , நோய் எதிர்ப்பு சக்தி மற்றும் உயிரியல் ப்ராடக்ட்ஸ் ,